Belimumab is a monoclonal antibody that specifically targets and inhibits the activity of B-lymphocyte stimulator (BLyS), a protein that plays a crucial role in the survival and proliferation of B cells. It is primarily used in the treatment of systemic lupus erythematosus (SLE), an autoimmune disease characterized by the overproduction of antibodies and inflammation. Belimumab is administered via subcutaneous injection or intravenous infusion, and its mechanism of action involves reducing the number of circulating B cells and decreasing the production of autoantibodies, thereby helping to manage disease activity. The drug is generally well-tolerated, but potential side effects may include infusion reactions, infections, and hypersensitivity reactions. As a biologic therapy, belimumab represents a targeted approach to modulating the immune system, offering a treatment option for patients with SLE who have not responded adequately to standard therapies. Its development has contributed to the understanding of the role of B cells in autoimmune diseases and has paved the way for further research into similar therapeutic agents.

Belimumab

356547-88-1: Belimumab is a monoclonal antibody that specifically targets and inhibits the activity of B-lymphocyte stimulator (BLyS), a protein that plays a crucial role in the survival and proliferation of B cells. It is primarily used in the treatment of systemic lupus erythematosus (SLE), an autoimmune disease characterized by the overproduction of antibodies and inflammation. Belimumab is administered via subcutaneous injection or intravenous infusion, and its mechanism of action involves reducing the number of circulating B cells and decreasing the production of autoantibodies, thereby helping to manage disease activity. The drug is generally well-tolerated, but potential side effects may include infusion reactions, infections, and hypersensitivity reactions. As a biologic therapy, belimumab represents a targeted approach to modulating the immune system, offering a treatment option for patients with SLE who have not responded adequately to standard therapies. Its development has contributed to the understanding of the role of B cells in autoimmune diseases and has paved the way for further research into similar therapeutic agents.

Belimumab, a human IgG1λ monoclonal antibody, blocks BAFF, treating lupus and related fatigue.

CAS 356547-88-1

Belimumab

Belimumab

Ref: TM-T76957

Belimumab

Ref: 3D-CLA1649